Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia
Condition(s):Refractory Aplastic AnemiaLast Updated:August 30, 2022Terminated
Hide Studies Not Open or Pending
Condition(s):Refractory Aplastic AnemiaLast Updated:August 30, 2022Terminated
Condition(s):Recurrent EpendymomaLast Updated:June 22, 2023Recruiting
Condition(s):Myelodysplastic SyndromeLast Updated:November 15, 2018Completed
Condition(s):Myelodysplastic SyndromesLast Updated:September 9, 2016Unknown status
Condition(s):Leukemia; Myelodysplastic SyndromesLast Updated:November 15, 2018Completed
Condition(s):Ovarian CancerLast Updated:February 8, 2024Recruiting
Condition(s):Acute Myelogenous Leukemia; Myelodysplastic SyndromeLast Updated:September 13, 2013Completed
Condition(s):Myelodysplastic Syndromes and Leukemia, Myeloid, AcuteLast Updated:June 4, 2013Completed
Condition(s):Induction Chemotherapy; Acute T-Lymphocytic Leukemia; T-cell Lymphoblastic Lymphoma Leukemia; T-cell/Myeloid Mixed Phenotype Acute LeukemiaLast Updated:June 24, 2020Unknown status
Condition(s):Previously Treated Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic SyndromeLast Updated:March 21, 2024Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.